Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study

Acadia Pharmaceuticals (ACAD.O) said on Monday its antipsychotic drug failed to significantly improve negative symptoms of schizophrenia, including poor socialization and lack of motivation, in a late-stage study.